H.C. Wainwright analyst Edward White reiterated a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $4.00. The company's shares closed last Wednesday at $1.68, close to its 52-week low of $1.35. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.1% and a 19.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Clovis Oncology has an analyst consensus of Hold, with a price target consensus of $2.75.
https://www.tipranks.com/news/blurbs/clovis-oncology-clvs-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Clovis Oncology Charts.
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Clovis Oncology Charts.